Gapping up
In reaction to strong earnings/guidance:
- CLDR +12.9%, DCI +11.3%, VRNT +10.3%, SECO +7.7%, AVAV +7.4%, GIII +6.7%, MBUU +4.6%, NAV +4.2%, CTRP +3.1%, FUN +1.9%
Other news:
- EYPT +17.5% (announced that Centers for Medicare and Medicaid Services approved transitional pass-through status and reimbursement through a C-code for DEXYCUTM 9%)
- NVCR +8.9% (reports Tumor Treating Fields plus chemotherapy extends median overall survival by 6.1 months in STELLAR Ph 2 registration trial in mesothelioma compared to historical control; to host investor briefing Sept 25)
- ARWR +8.2% (will present initial clinical data for ARO-HBV at the 18th World Gastroenterologists Summit)
- SPPI +7.6% (reports new interim data from the EGFR cohort and for the first time the HER2 cohort in the MD Anderson Phase 2 trial; Updated data will be presented Sept 24 and will include data into September)
- MXWL +6.6% (announced grid energy storage subsystem design-in with Siemens)
- LHO +1.4% (LaSalle Hotel's Board of Trustees determines that Pebblebrook Hotel Trust's (PEB) unsolicited, non-binding proposal does constitute a 'superior proposal' to Blackstone (BX) transaction )
- DWDP +1.1% (files mixed securities shelf offering )
- ATRA +0.9% (enters into a strategic collaboration with Moffitt Cancer Center)
Analyst comments:
- VOD +1.3% (upgraded to Buy from Neutral at Citigroup)
- TCF +0.9% (upgraded to Buy at BofA/Merrill)
![]()